# PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Source: https://onco.cc/trials/nct06617481/  
OnCo record `nct06617481` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Flotufolastat F-18 in Prostate cancer, run by AdventHealth, now recruiting.

## Summary

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence is a phase 2 interventional study registered as NCT06617481 by AdventHealth, with 30 participants planned, started 2024-09-20 and due to reach its primary completion in 2027-09-05. Interventions recorded: 18F-rhPSMA-7.3 (Posluma). Conditions recorded: Prostate Cancer (Post Prostatectomy).

Linked to the drug Flotufolastat F-18 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06617481
- Phase: 2
- Setting: RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence
- Sponsor: AdventHealth
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06617481: https://clinicaltrials.gov/study/NCT06617481

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Flotufolastat F-18](https://onco.cc/drugs/flotufolastat/)

---
JSON: https://onco.cc/api/v1/entities/nct06617481.json